↓ Skip to main content

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

Overview of attention for article published in Cardiovascular Diabetology, August 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (62nd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
108 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Published in
Cardiovascular Diabetology, August 2016
DOI 10.1186/s12933-016-0431-4
Pubmed ID
Authors

Angelo Avogaro, Gian Paolo Fadini, Giorgio Sesti, Enzo Bonora, Stefano Del Prato

Abstract

Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of glucose-lowering medications increases, clinicians have to consider several open questions in the management of type 2 diabetes, one of which is the cardiovascular risk profile of each regimen. Recent placebo-controlled cardiovascular outcome trials (CVOTs) have responded to some of these questions, but careful interpretation is needed. After general disappointment around CVOTs assessing safety of DPP-4 inhibitors (SAVOR, TECOS, EXAMINE) and the GLP-1 receptor agonist lixisenatide (ELIXA), the EMPA-REG Outcome trial and the LEADER trial have shown superiority of the SGLT2-I empagliflozin and the GLP-1RA liraglutide, respectively, on the 3-point MACE outcome (cardiovascular death, non-fatal myocardial infarction or stroke) and cardiovascular, as well as all-cause mortality. While available mechanistic studies largely support a cardioprotective effect of GLP-1, the ability of SGLT2 inhibitor(s) to prevent cardiovascular death was unexpected and deserves future investigation. We herein review the results of completed CVOTs of glucose-lowering medications and suggest a possible treatment algorithm based on cardiac and renal co-morbidities to translate CVOT findings into clinical practice.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 108 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 20%
Researcher 20 19%
Other 11 10%
Student > Ph. D. Student 10 9%
Student > Bachelor 8 7%
Other 21 19%
Unknown 16 15%
Readers by discipline Count As %
Medicine and Dentistry 58 54%
Pharmacology, Toxicology and Pharmaceutical Science 12 11%
Biochemistry, Genetics and Molecular Biology 5 5%
Economics, Econometrics and Finance 5 5%
Nursing and Health Professions 2 2%
Other 5 5%
Unknown 21 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2017.
All research outputs
#5,850,324
of 11,338,956 outputs
Outputs from Cardiovascular Diabetology
#213
of 661 outputs
Outputs of similar age
#98,143
of 264,554 outputs
Outputs of similar age from Cardiovascular Diabetology
#7
of 37 outputs
Altmetric has tracked 11,338,956 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 661 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,554 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.